Literature DB >> 27770655

Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice.

Flavia da Cunha Vasconcelos1, Marcos Antonio Mauricio Scheiner1, Arthur Moellman-Coelho2, André Luiz Mencalha3, Ilana Zalcberg Renault4, Vivian Mary Rumjanek5, Raquel Ciuvalschi Maia6.   

Abstract

Despite the favorable clinical evolution of patients with chronic myeloid leukemia (CML), resistance or intolerance to imatinib is present in approximately 35% of patients. Sokal score is a widely used risk factor, however efflux and influx transporters are provisional risk factors implicated in imatinib resistance. This study analyzed Sokal score, ABCB1, ABCG2 and OCT1 mRNA transporter expression levels as well as P-glycoprotein expression and efflux transporters activity to seek a possible correlation between these factors and the molecular response at 12 months from imatinib start as well as 8-year overall survival (OS). Low plus intermediate Sokal score correlated to optimal imatinib responses, as well as OS at 8-years, thus confirming the established role of Sokal score as a prognostic factor in CML patients. Low ABCB1 and high OCT1 mRNA levels were associated with an optimal molecular response, while the inverse levels were associated with non-responders (warning and failure) patients. Our results suggest that ABCB1 and OCT1 mRNA expressions may present biological relevance to identify responder and non-responder patients to imatinib treatment. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ABCB1/P-glycoprotein; ABCG2; Chronic myeloid leukemia; Imatinib; OCT1; Sokal score

Mesh:

Substances:

Year:  2016        PMID: 27770655     DOI: 10.1016/j.leukres.2016.10.005

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  8 in total

Review 1.  Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia.

Authors:  Aritro Nath; Jacqueline Wang; R Stephanie Huang
Journal:  Mol Diagn Ther       Date:  2017-12       Impact factor: 4.074

2.  Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia.

Authors:  Raquel Alves; Ana Cristina Gonçalves; Joana Jorge; António M Almeida; Ana Bela Sarmento-Ribeiro
Journal:  Biomedicines       Date:  2022-05-17

3.  PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase.

Authors:  Juan M Alonso-Dominguez; Luis Felipe Casado; Eduardo Anguita; Maria Teresa Gomez-Casares; Ismael Buño; Francisca Ferrer-Marín; Alicia Arenas; Rafael Del Orbe; Rosa Ayala; Pilar Llamas; Rocio N Salgado; Santiago Osorio; Pedro Sanchez-Godoy; Carmen Burgaleta; Ignacio Mahíllo-Fernández; Valentin Garcia-Gutierrez; Juan Luis Steegmann; Joaquín Martinez-Lopez
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

4.  Metabolic Reprogramming During Multidrug Resistance in Leukemias.

Authors:  Raphael Silveira Vidal; Julia Quarti; Mariana Figueiredo Rodrigues; Franklin D Rumjanek; Vivian M Rumjanek
Journal:  Front Oncol       Date:  2018-04-04       Impact factor: 6.244

Review 5.  Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia.

Authors:  Raquel C Maia; Flavia C Vasconcelos; Paloma S Souza; Vivian M Rumjanek
Journal:  Molecules       Date:  2018-01-07       Impact factor: 4.411

6.  Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib.

Authors:  Federica Loscocco; Giuseppe Visani; Annamaria Ruzzo; Irene Bagaloni; Fabio Fuligni; Sara Galimberti; Antonello Di Paolo; Fabio Stagno; Patrizia Pregno; Mario Annunziata; Antonella Gozzini; Sara Barulli; Elisa Gabucci; Mauro Magnani; Alessandro Isidori
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

Review 7.  Pharmacogenetics of Drugs Used in the Treatment of Cancers.

Authors:  Beata Franczyk; Jacek Rysz; Anna Gluba-Brzózka
Journal:  Genes (Basel)       Date:  2022-02-07       Impact factor: 4.096

8.  Deciphering Key Pharmacological Pathways of Qingdai Acting on Chronic Myeloid Leukemia Using a Network Pharmacology-Based Strategy.

Authors:  Huayao Li; Lijuan Liu; Cun Liu; Jing Zhuang; Chao Zhou; Jing Yang; Chundi Gao; Gongxi Liu; Qingliang Lv; Changgang Sun
Journal:  Med Sci Monit       Date:  2018-08-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.